Please carry this card with you at all times and show it to all emergency and healthcare providers (including pharmacists, nurses and dentists) involved in your care to inform them about your treatment with LEMTRADA® ▼ (alemtuzumab).

IMPORTANT SIDE EFFECTS TO WATCH FOR:

Serious infections, such as, PML (progressive multifocal leukoencephalopathy)

Serious side effects occurring shortly after alemtuzumab infusion (usually within 1-3 days of infusion)

- Myocardial ischaemia and/or myocardial infarction (heart attack)
- Stroke and Cervicocephalic arterial dissection (tears in blood vessels supplying the brain)
- Pulmonary alveolar haemorrhage (bleeding in the lungs)
- Thrombocytopenia

Immune-mediated reactions (which can occur months to years after infusion)

- Thyroid disorders
- Immune Thrombocytopenic Purpura (ITP)
- Kidney problems including anti-Glomerular Basement Membrane (GBM) disease
- Autoimmune hepatitis
- Haemophagocytic Lymphohistiocytosis (HLH)
- Acquired haemophilia A
- Thrombotic thrombocytopenic purpura (TTP)
- Adult Onset Still's Disease (AOSD)
- Autoimmune encephalitis (AIE)

What you should know about alemtuzumab

Call your neurologist right away to report any symptoms of the above conditions, no matter if they are new, worsening or returning symptoms. Seek medical attention if you cannot reach your own doctor, and make sure you show them this card.

Patients, please see Patient Information Leaflet (PIL) and Patient Guide for more information.

Job code: MAT-XU-2300662 (v1.0) Date of preparation: February 2023. MHRA approval date: February 2023.

LEMTRADA ▼ (ALEMTUZUMAB) PATIENT ALERT CARD – UK

I have been treated with alemtuzumab, a treatment for Multiple Sclerosis (MS), which affects the immune system. I am participating in a risk monitoring programme which continues for at least 48 months after my last treatment. Although, delayed side effects may occur beyond 48 months. Patients and caregivers must continue to look out for the signs, even after monthly tests are no longer required.

Alemtuzumab treatment may increase the risk of:

- Immune-mediated reactions such as thyroid disorders, Immune Thrombocytopenic Purpura (ITP), Thrombotic thrombocytopenic purpura (TTP), nephropathies, including anti-Glomerular Basement Membrane (anti- GBM) disease, Autoimmune Hepatitis (AIH), acquired haemophilia A, Haemophagocytic Lymphohistiocytosis (HLH), Adult Onset Still's Disease (AOSD) and Autoimmune Encephalitis (AIE)
- Serious infections
- Serious reactions temporally associated with alemtuzumab infusion, including myocardial ischaemia, haemorrhagic stroke, cervico-cephalic arterial dissection, pulmonary alveolar haemorrhage and thrombocytopenia.

HCPs, please see full Summary of Product Characteristics (SmPC) for more information.

Job code: MAT-XU-2300662 (v1.0) Date of preparation: February 2023. MHRA approval date: February 2023.

My neurologist prescribing alemtuzumab can be contacted via phone using the details below.

Neurologist name: .....

Neurologist contact number: .....

Last alemtuzumab infusion: .....

Delayed side effects may occur beyond 48 months. Therefore you must continue to look out for the signs, even after your monthly tests are no longer required.

Please report suspected adverse drug reactions (ADRs) to the MHRA through the Yellow Card scheme, via the Yellow Card website www.mhra.gov.uk/yellowcard, the free Yellow Card app available in Apple App Store or Google Play Store, and also some clinical IT systems for healthcare professionals. Alternatively you can call 0800 731 6789 for free, Monday to Friday between 9am and 5pm.

By reporting side effects, you can help provide more information on the safety of this medicine. Side effects should also be reported to Sanofi: Tel: 0800 0902314. Email: uk-drugsafety@sanofi.com

Job code: MAT-XU-2300662 (v1.0) Date of preparation: February 2023. MHRA approval date: February 2023.